Aeris Therapeutics, Inc.’ AeriSeal® System Clinical Data Demonstrate Improved Lung Function for up to One Year in Advanced Emphysema Patients, Publication Accepted in CHEST
6/21/2012 10:53:08 AM
WOBURN, Mass.--(BUSINESS WIRE)--Aeris Therapeutics, LLC announced today the publication in CHEST of data from its latest AeriSeal® System clinical trial. In the study, patients with advanced emphysema were treated with the AeriSeal System under conscious sedation. Patients experienced improved lung function for up to one year following the AeriSeal System treatment, with results similar to those reported following lung volume reduction surgery (LVRS). The data from the study are included in a publication entitled, “Bilateral Endoscopic Sealant Lung Volume Reduction Therapy for Advanced Emphysema,” which appears online as a CHEST Paper in Press (DOI 10.1378/chest.12-0421). The AeriSeal System is a minimally invasive treatment designed to reduce lung volume and improve breathing function and symptoms in patients with advanced emphysema who no longer respond to standard medical therapy. The AeriSeal System is now entering a multi-national pivotal clinical study.
comments powered by